financetom
Business
financetom
/
Business
/
Spirit maker MGP Ingredients Q2 sales beat estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Spirit maker MGP Ingredients Q2 sales beat estimates
Jul 31, 2025 4:56 AM

Overview

* MGP Ingredients ( MGPI ) Q2 sales fall 24% to $145.5 mln, beating analyst expectations

* Adjusted EPS drops 43% to $0.97, no analyst estimate provided

* Co reaffirms 2025 sales and adjusted earnings outlook

Outlook

* MGP Ingredients ( MGPI ) projects 2025 sales between $520 mln and $540 mln

* Company expects adjusted EBITDA for 2025 between $105 mln and $115 mln

* MGP Ingredients ( MGPI ) sees adjusted EPS for 2025 in the range of $2.45 to $2.75

* Company revises full-year capital expenditures to approximately $32.5 mln

Result Drivers

* BROWN GOODS DECLINE - Reduced customer demand for brown goods due to elevated industry-wide barrel inventories impacted sales, per co

* PROACTIVE ENGAGEMENT - Brown goods sales volume and pricing met expectations due to proactive customer engagement

* PREMIUM PLUS GROWTH - Penelope brand drove growth in premium plus sales within Branded Spirits segment

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $145.50 $139.40

mln mln (6

Analysts

)

Q2 Net $14.40

Income mln

Q2 $35.90

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the distillers & wineries peer group is "buy"

* Wall Street's median 12-month price target for MGP Ingredients Inc ( MGPI ) is $39.50, about 25.6% above its July 30 closing price of $29.37

* The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GE HealthCare to buy Intelerad for $2.3 billion to expand in outpatient care market
GE HealthCare to buy Intelerad for $2.3 billion to expand in outpatient care market
Nov 20, 2025
Nov 20 (Reuters) - GE HealthCare ( GEHC ) said on Thursday it will acquire medical imaging software provider Intelerad for $2.3 billion in cash as the medical device maker seeks to expand into outpatient care markets. The deal gives GE HealthCare ( GEHC ), whose equipment are prominent in hospitals, access to Intelerad's cloud-based medical imaging software and other...
Brookfield to Redeem C$850 Million in Notes Early
Brookfield to Redeem C$850 Million in Notes Early
Nov 20, 2025
04:59 PM EST, 11/20/2025 (MT Newswires) -- Brookfield (BN.TO) after trade Thursday said it will redeem its C$850 million of its 4.82% medium-term notes due January 2026. The redemption will take place on Dec. 22, at a price equal to par, plus accrued and unpaid interest up to, but not including, the redemption date, the company added. ...
Jericho Energy and Smartkem Extend LOI for Proposed All-Stock Merger to Form a U.S.-Owned, Nasdaq-Listed AI Infrastructure Company
Jericho Energy and Smartkem Extend LOI for Proposed All-Stock Merger to Form a U.S.-Owned, Nasdaq-Listed AI Infrastructure Company
Nov 20, 2025
Proposed all-stock transaction aims to align JEV's scalable energy platform with Smartkem ( SMTK )'s semiconductor innovations to power next generation AI data centers TULSA, OK / ACCESS Newswire / November 20, 2025 / Jericho Energy Ventures Inc. ( JROOF ) (Jericho, JEV or the Company), an energy innovation company positioned at the nexus of energy and AI infrastructure, announces...
ClearPoint Neuro Completes Acquisition of IRRAS
ClearPoint Neuro Completes Acquisition of IRRAS
Nov 20, 2025
Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 20, 2025 / ClearPoint Neuro, Inc. ( CLPT ) (the Company), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has...
Copyright 2023-2026 - www.financetom.com All Rights Reserved